The company said STADA will market and distribute two biosimilars developed by CuraTeQ that have been approved by the European Medicines Agency (EMA). The agreement covers select EU markets, including France and Germany.
CuraTeQ said new brand names will be created and registered for each biosimilar under the arrangement. The subsidiary focuses on biosimilars and is part of Aurobindo Pharma’s biologics business.
Also Read: USFDA action on Eugia unit II puts Aurobindo Pharma shares in focus
According to the company, the agreement will involve STADA using its distribution network across the EU markets to market and distribute the two biosimilars developed by CuraTeQ.
Last week, Aurobindo Pharma said its wholly owned subsidiary, Apitoria Pharma Pvt Ltd, has received a ‘Voluntary Action Indicated’ (VAI) classification from the US Food and Drug Administration (USFDA) for its Unit-V manufacturing facility.
The USFDA inspected the API manufacturing facility in Telangana between December 1 and December 12, 2025, following which a Form 483 with three observations was issued.
Also Read: FDA flags Aurobindo Pharma’s Eugia unit after inspection; issues 9 observations
Subsequently, the unit has now received an Establishment Inspection Report (EIR) classifying the facility as VAI, indicating that the inspection is closed. The VAI classification means that while certain observations were noted during the inspection, they do not warrant regulatory or enforcement action by the USFDA.
Shares of Aurobindo Pharma Ltd ended at ₹1,308.00, up by ₹26.75, or 2.09%, on the BSE.
Also Read: Aurobindo Pharma shares gain post Q3; Street eyes management commentary
(Edited by : Jomy Jos Pullokaran)
First Published:Â Mar 25, 2026 5:27 PM IST
